Get the Stockscreener App
0.67
13.12%
0.0777
After Hours:
.68
0.01
+1.49%
Jaguar Health Inc stock is traded at $0.67, with a volume of 506.82K.
It is up +13.12% in the last 24 hours and down -40.71% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$0.5923
Open:
$0.5907
24h Volume:
506.82K
Relative Volume:
0.15
Market Cap:
$2.80M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.0414
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
-0.68%
1M Performance:
-40.71%
6M Performance:
-69.89%
1Y Performance:
-96.83%
1-Day Range:
$0.59
$0.68
1-Week Range:
$0.56
$0.6831
52-Week Range:
$0.56
$25.75
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.67 | 2.47M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million - South Bend Tribune
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts - The Marion Star
Should value investors consider Jaguar Health Inc.July 2025 Opening Moves & Weekly Breakout Watchlists - mfd.ru
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue - hattiesburgamerican.com
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - The Asheville Citizen Times
Jaguar Health Executes Debt-Reducing Equity Warrant Transactions - TipRanks
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - citizen-times.com
Jaguar Health Signs Multiple Material Agreements - TradingView
Jaguar Health (JAGX) Advances Rare Disease Program with Focus on Crofelemer - GuruFocus
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi - Lansing State Journal
Jaguar trial cuts children’s IV support needs by up to 37% - Stock Titan
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - barnstablepatriot.com
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Pueblo Chieftain
Earnings Report: Is Jaguar Health Inc a defensive stock2025 Valuation Update & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication - dailycommercial.com
Recent Developments in Jaguar Health - StocksToTrade
Strategic Licensing Boosts Jaguar Health’s Market Momentum - timothysykes.com
Swing Trade: Is Jaguar Health Inc on track to beat earningsJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Jaguar Health Enters Exclusive Licensing Agreement Boosting Market Dynamics - timothysykes.com
The Surge In Jaguar Health Stock: What's Happening Now? - Sahm
Jaguar Health’s Licensing Deal Boosts Financial Prospects - StocksToTrade
Jaguar Health Soars Amid Licensing Deals and Study Breakthroughs - timothysykes.com
Jaguar Health Inc surges amid market gains - Intellectia AI
Jaguar Health IncCo & unit entered license agreement with Woodward Specialty LLCSEC filing - marketscreener.com
Jaguar Animal Health Grants U.S. Rights to Crofelemer Drugs - TipRanks
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):